when a professional videographer gets to work. This is for the #ECTRIMS 2025 congress. Proud to contribute. www.youtube.com/watch?v=O82D...
ECTRIMS 2025 Special Feature: Prof. Burkhard Becher on Cell Trafficking and Immune Cells in the CNS
YouTube video by ECTRIMS Congress
www.youtube.com
May 13, 2025 at 3:09 PM
when a professional videographer gets to work. This is for the #ECTRIMS 2025 congress. Proud to contribute. www.youtube.com/watch?v=O82D...
For #MSFriday here's a link to a webinar on the latest #multiplesclerosis research from ECTRIMS 2024. Note that there's no audio for the first 10 seconds
youtu.be/3ADO7NvUYzo?...
youtu.be/3ADO7NvUYzo?...
ECTRIMS 2024 - Insight into the latest MS research
YouTube video by Overcoming MS
youtu.be
December 6, 2024 at 11:58 AM
For #MSFriday here's a link to a webinar on the latest #multiplesclerosis research from ECTRIMS 2024. Note that there's no audio for the first 10 seconds
youtu.be/3ADO7NvUYzo?...
youtu.be/3ADO7NvUYzo?...
Professor Christoph Kleinschnitz erwähnt zu Beginn seines Vortrags an der ECTRIMS, dass er kürzlich „eine schwere Erkältung“ hatte.
Soso. COVID-19? Gute Besserung… 😏
Soso. COVID-19? Gute Besserung… 😏
October 12, 2023 at 7:14 AM
Professor Christoph Kleinschnitz erwähnt zu Beginn seines Vortrags an der ECTRIMS, dass er kürzlich „eine schwere Erkältung“ hatte.
Soso. COVID-19? Gute Besserung… 😏
Soso. COVID-19? Gute Besserung… 😏
Higher doses of ocrevus were not more effective than standard doses in the Phase 3b GAVOTTE trial multiplesclerosisnewstoday.com/ectrims/2025...
ECTRIMS 2025: Standard Ocrevus dose holds up in PPMS
Topline trial data showed that a higher Ocrevus dose didn't provide more benefit than the standard regimen in people with PPMS.
multiplesclerosisnewstoday.com
October 6, 2025 at 5:25 AM
Higher doses of ocrevus were not more effective than standard doses in the Phase 3b GAVOTTE trial multiplesclerosisnewstoday.com/ectrims/2025...
Hope your Saturday has been ok, people with #MS?
You can join the ECTRIMS patient session online if you’re interested- & ask questions!
Gavin Giovannoni’s MS Selfie site has the details
You can join the ECTRIMS patient session online if you’re interested- & ask questions!
Gavin Giovannoni’s MS Selfie site has the details
September 14, 2024 at 4:08 PM
Hope your Saturday has been ok, people with #MS?
You can join the ECTRIMS patient session online if you’re interested- & ask questions!
Gavin Giovannoni’s MS Selfie site has the details
You can join the ECTRIMS patient session online if you’re interested- & ask questions!
Gavin Giovannoni’s MS Selfie site has the details
#MedSky / #NeuroSky, follow @antojm.bsky.social ! 🇫🇷Antony is the Head of Association Management (Congrex) & #ECTRIMS Executive Manager.
ECTRIMS is the largest global annual meeting dedicated to #MS, #NMOSD, #MOGAD & other demyelinating conditions. See you in Barcelona 🇪🇸 September 24-26, 2025 🧠
ECTRIMS is the largest global annual meeting dedicated to #MS, #NMOSD, #MOGAD & other demyelinating conditions. See you in Barcelona 🇪🇸 September 24-26, 2025 🧠
November 25, 2024 at 8:39 AM
It's never too early to get excited for ECTRIMS Patient Community Day 2025!
Save the date for a day dedicated to #MOGAD, #MS and #NMOSD patients on September 26th in Barcelona 🇪🇸
Until then, watch replays from the 2024 🇩🇰 event in 6 languages here: www.youtube.com/watch?v=q8yJ...
Save the date for a day dedicated to #MOGAD, #MS and #NMOSD patients on September 26th in Barcelona 🇪🇸
Until then, watch replays from the 2024 🇩🇰 event in 6 languages here: www.youtube.com/watch?v=q8yJ...
ECTRIMS 2024 Patient Community Day - ENGLISH
YouTube video by ECTRIMS Congress
www.youtube.com
February 27, 2025 at 1:13 PM
It's never too early to get excited for ECTRIMS Patient Community Day 2025!
Save the date for a day dedicated to #MOGAD, #MS and #NMOSD patients on September 26th in Barcelona 🇪🇸
Until then, watch replays from the 2024 🇩🇰 event in 6 languages here: www.youtube.com/watch?v=q8yJ...
Save the date for a day dedicated to #MOGAD, #MS and #NMOSD patients on September 26th in Barcelona 🇪🇸
Until then, watch replays from the 2024 🇩🇰 event in 6 languages here: www.youtube.com/watch?v=q8yJ...
Who going to ECTRIMS in Barcelona wants to join me to eat all of the things?
September 7, 2025 at 11:52 PM
Who going to ECTRIMS in Barcelona wants to join me to eat all of the things?
Preserving cognitive function & reserves was discussed at ECTRIMS today. As important as physical exercise.
I’m going to re-read the entire canon of Henry James’ novels! That should work! 😂
#MS
I’m going to re-read the entire canon of Henry James’ novels! That should work! 😂
#MS
September 20, 2024 at 5:13 PM
Preserving cognitive function & reserves was discussed at ECTRIMS today. As important as physical exercise.
I’m going to re-read the entire canon of Henry James’ novels! That should work! 😂
#MS
I’m going to re-read the entire canon of Henry James’ novels! That should work! 😂
#MS
It does….
I attended ECTRIMS patients session online this year : remyelination & vaccines were talked of as real outcomes in future years
I attended ECTRIMS patients session online this year : remyelination & vaccines were talked of as real outcomes in future years
November 27, 2024 at 4:23 PM
It does….
I attended ECTRIMS patients session online this year : remyelination & vaccines were talked of as real outcomes in future years
I attended ECTRIMS patients session online this year : remyelination & vaccines were talked of as real outcomes in future years
Ruby-throated hummingbirds are migrating now. Small but mighty, they're the symbol the MOGAD community chose for its tenacity. 🐦
One month out: join The MOG Project, an ECTRIMS supporting partner, virtually on Oct 23 to learn about MOGAD, MS, NMOSD & more.
www.ectrimspatientcommunity.eu
One month out: join The MOG Project, an ECTRIMS supporting partner, virtually on Oct 23 to learn about MOGAD, MS, NMOSD & more.
www.ectrimspatientcommunity.eu
September 23, 2026 at 12:36 AM
Ruby-throated hummingbirds are migrating now. Small but mighty, they're the symbol the MOGAD community chose for its tenacity. 🐦
One month out: join The MOG Project, an ECTRIMS supporting partner, virtually on Oct 23 to learn about MOGAD, MS, NMOSD & more.
www.ectrimspatientcommunity.eu
One month out: join The MOG Project, an ECTRIMS supporting partner, virtually on Oct 23 to learn about MOGAD, MS, NMOSD & more.
www.ectrimspatientcommunity.eu
Dr Xin Lin from our MS Research Flagship is at #ECTRIMS2025! His poster reveals how genetic structural variation in complement component 4 affects risk of MS onset and disability progression.
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
September 25, 2025 at 3:01 AM
Dr Xin Lin from our MS Research Flagship is at #ECTRIMS2025! His poster reveals how genetic structural variation in complement component 4 affects risk of MS onset and disability progression.
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
📍 @ECTRIMS 2025, Barcelona 🗓️ 24 September
Session on cutting-edge research on EBV & #MS development + therapeutic interventions
🔗 Register: bit.ly/4kIda1U
Visit EMSP booth #11 at #ECTRIMS2025 to learn more about our projects.
Session on cutting-edge research on EBV & #MS development + therapeutic interventions
🔗 Register: bit.ly/4kIda1U
Visit EMSP booth #11 at #ECTRIMS2025 to learn more about our projects.
ECTRIMS 2025 - HOME
ECTRIMS 2025 is the premier meeting place to collaborate on the next life-changing research and treatment options for people with MS and related diseases.
bit.ly
June 13, 2025 at 12:02 PM
📍 @ECTRIMS 2025, Barcelona 🗓️ 24 September
Session on cutting-edge research on EBV & #MS development + therapeutic interventions
🔗 Register: bit.ly/4kIda1U
Visit EMSP booth #11 at #ECTRIMS2025 to learn more about our projects.
Session on cutting-edge research on EBV & #MS development + therapeutic interventions
🔗 Register: bit.ly/4kIda1U
Visit EMSP booth #11 at #ECTRIMS2025 to learn more about our projects.
Back from #ECTRIMS2025 in Barcelona! Where Claudia Rodriguez-Lopez masterfully presented our work “Progressive demyelination, neuroinflammation and disability by brain TAF1 alteration found in #multiple_sclerosis”, selected for Best of ECTRIMS Slide Deck!
@cbm-csic-uam.bsky.social
@uam.es @csic.es
@cbm-csic-uam.bsky.social
@uam.es @csic.es
September 30, 2025 at 5:33 PM
Back from #ECTRIMS2025 in Barcelona! Where Claudia Rodriguez-Lopez masterfully presented our work “Progressive demyelination, neuroinflammation and disability by brain TAF1 alteration found in #multiple_sclerosis”, selected for Best of ECTRIMS Slide Deck!
@cbm-csic-uam.bsky.social
@uam.es @csic.es
@cbm-csic-uam.bsky.social
@uam.es @csic.es
Thank you #ECTRIMS for giving clinician scientists like Muriel Schraad the opportunity to present their work to such a diverse and impactful community.
September 25, 2025 at 1:46 PM
Thank you #ECTRIMS for giving clinician scientists like Muriel Schraad the opportunity to present their work to such a diverse and impactful community.
We believe that research should reach the people it impacts most.
That’s why we’re supporting Patient Community Day 2026 – bringing together a global community to learn, share, and better understand the future of #MS, #NMOSD, and #MOGAD care.
👉 Join the conversation: buff.ly/AHhD0rI
#ECTRIMS
That’s why we’re supporting Patient Community Day 2026 – bringing together a global community to learn, share, and better understand the future of #MS, #NMOSD, and #MOGAD care.
👉 Join the conversation: buff.ly/AHhD0rI
#ECTRIMS
August 28, 2026 at 12:01 PM
We believe that research should reach the people it impacts most.
That’s why we’re supporting Patient Community Day 2026 – bringing together a global community to learn, share, and better understand the future of #MS, #NMOSD, and #MOGAD care.
👉 Join the conversation: buff.ly/AHhD0rI
#ECTRIMS
That’s why we’re supporting Patient Community Day 2026 – bringing together a global community to learn, share, and better understand the future of #MS, #NMOSD, and #MOGAD care.
👉 Join the conversation: buff.ly/AHhD0rI
#ECTRIMS
Our MS Research Flagship's Himanshu Saraswat is at #ECTRIMS2025! His study investigated whether rare genetic variants in families with multiple MS cases could help explain MS risk.
More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
September 25, 2025 at 3:06 AM
Our MS Research Flagship's Himanshu Saraswat is at #ECTRIMS2025! His study investigated whether rare genetic variants in families with multiple MS cases could help explain MS risk.
More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
Could you possibly do maybe a top 5 what you found interesting in this year's ECTRIMS?
October 14, 2025 at 4:53 AM
Could you possibly do maybe a top 5 what you found interesting in this year's ECTRIMS?
ECTRIMS 2024
Sign up to tune in online, for free. I certainly will be doing so!
While Prof Gavin Giovannoni is no longer doing clinical work, he’s still heavily involved in the #MS world
ectrims.eu/ectrims2024-...
Sign up to tune in online, for free. I certainly will be doing so!
While Prof Gavin Giovannoni is no longer doing clinical work, he’s still heavily involved in the #MS world
ectrims.eu/ectrims2024-...
ECTRIMS2024 - ECTRIMS Patient Community Day
ectrims.eu
August 8, 2024 at 3:20 PM
ECTRIMS 2024
Sign up to tune in online, for free. I certainly will be doing so!
While Prof Gavin Giovannoni is no longer doing clinical work, he’s still heavily involved in the #MS world
ectrims.eu/ectrims2024-...
Sign up to tune in online, for free. I certainly will be doing so!
While Prof Gavin Giovannoni is no longer doing clinical work, he’s still heavily involved in the #MS world
ectrims.eu/ectrims2024-...
Our MS Research Flagship's Panteha Khaledi presents her poster at #ECTRIMS2025! Her study explores how the immune system’s T cells respond to Epstein-Barr virus (EBV) in people with #MultipleSclerosis
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MSResearch
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MSResearch
September 26, 2025 at 12:48 AM
Our MS Research Flagship's Panteha Khaledi presents her poster at #ECTRIMS2025! Her study explores how the immune system’s T cells respond to Epstein-Barr virus (EBV) in people with #MultipleSclerosis
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MSResearch
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MSResearch
@antojm.bsky.social
Please consider adding Bluesky social media for #ECTRIMS announcements and research reports!
Please and thank you!
#MultipleSclerosis
Please consider adding Bluesky social media for #ECTRIMS announcements and research reports!
Please and thank you!
#MultipleSclerosis
November 25, 2024 at 12:32 PM
@antojm.bsky.social
Please consider adding Bluesky social media for #ECTRIMS announcements and research reports!
Please and thank you!
#MultipleSclerosis
Please consider adding Bluesky social media for #ECTRIMS announcements and research reports!
Please and thank you!
#MultipleSclerosis
New post: Q&A september ECTRIMS month https://multiple-sclerosis-research.org/2025/08/qa-september-ectrims-month/
August 31, 2025 at 10:01 PM
New post: Q&A september ECTRIMS month https://multiple-sclerosis-research.org/2025/08/qa-september-ectrims-month/
The O-HAND trial: Ocrevus showed benefits in primary progressive MS [data presented at ECTRIMS, unpublished]. 30% reduction in a composite disability endpoint compared to placebo. www.neurologylive.com/view/underst....
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, lead investigator of the phase 3 ORATORIO-HAND trial, provided comment on the results presented at ECTRIMS 2025, highlighting ocrelizumab’s therapeuti...
www.neurologylive.com
October 14, 2025 at 4:23 AM
The O-HAND trial: Ocrevus showed benefits in primary progressive MS [data presented at ECTRIMS, unpublished]. 30% reduction in a composite disability endpoint compared to placebo. www.neurologylive.com/view/underst....